title: First Report on Stem Cell Transplant From Iraq.
abstract: The Iraqi Bone Marrow Transplantation Center is located in the medical city complex of Bab Almuadham in Baghdad, Iraq. It was established on March 11, 2002, and performed its first mini-allotransplant for acute myeloid leukemia on January 24, 2003. Among 16 patients who received hematopoietic stem cell transplant between January 2003 and January 2010, one patient underwent allogeneic bone marrow transplant for acute myeloid leukemia and 15 patients received autologous bone marrow transplant for the following indications: 5 had multiple myeloma, 9 had lymphoma (8 with Hodgkin disease and 1 with non- Hodgkin lymphoma), and 1 had rhabdomyosarcoma. Median age was 34 years (range, 10-56 y), and our patient group included 8 females and 8 males. Of the 16 patients, 12 are still alive. The mortality rate was 25% as measured during our follow-up from 2 to 96 months. Of the 9 patients with lymphoma, 1 died and 2 relapsed after transplant. Therefore, our survival rate in lymphoma was 88%, with progression-free survival in lymphoma ranging from 2 to 66 months (mean survival of 13 mo, mode of 13 mo). For the 5 patients with multiple myeloma who received transplants, 1 died and 2 relapsed, with effective-free survival of 6 to 13 months. Our results show that high-dose chemotherapy followed by autologous stem cell transplant can induce long-term disease control in this cohort of patients with refractory or advanced Hodgkin disease; progression-free survival for our cohort was 50%, with survival comparable to those reported in the literature.
authors.affiliation: Department of General Surgery, Baskent University, Ankara, Turkey.
authors.forename: Abdul Majeed A
authors.initials: AM
authors.lastname: Hammadi
authors.forename: Waleed A
authors.initials: WA
authors.lastname: Azeez
authors.forename: Firas Hashim
authors.initials: FH
authors.lastname: Jasim
authors.forename: Nadher
authors.initials: N
authors.lastname: Alshammary
authors.forename: Adel D
authors.initials: AD
authors.lastname: Sewan
authors.forename: Khudhair
authors.initials: K
authors.lastname: Alrawaq
authors.forename: Ala
authors.initials: A
authors.lastname: Makki
authors.forename: Ahmed
authors.initials: A
authors.lastname: Mubarak
authors.forename: Amel
authors.initials: A
authors.lastname: Ameen
authors.forename: Andolina
authors.initials: A
authors.lastname: Marino
authors.forename: Ahmed
authors.initials: A
authors.lastname: Khudhair
authors.forename: Nedhal K
authors.initials: NK
authors.lastname: Alrahhal
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D002648:Child; D018450:Disease Progression; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007493:Iraq; D008223:Lymphoma / Q000175:diagnosis / Q000401:mortality / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000175:diagnosis / Q000401:mortality / Q000601:surgery*; D012008:Recurrence; D012086:Reoperation; D012208:Rhabdomyosarcoma / Q000175:diagnosis / Q000401:mortality / Q000601:surgery*; D033581:Stem Cell Transplantation / Q000009:adverse effects / Q000401:mortality; D013997:Time Factors; D016896:Treatment Outcome; D055815:Young Adult